Topical Timolol Beyond Infancy: A Retrospective Study of Its Use in Persistent Infantile Hemangiomas
Open Access
- 26 May 2026
- journal article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (7) , 3295-3306
Abstract
Infantile hemangiomas (IH) usually undergo spontaneous involution; however, some lesions remain visible after infancy and may cause psychosocial distress in children and their families. Evidence regarding the effectiveness of topical beta-blockers when treatment is initiated after infancy remains limited. This real-world study evaluated the efficacy of topical timolol therapy in children aged 1-5 years with persistent IH. Children with IH were evaluated at a specialized vascular anomalies center in Ukraine between 2019 and 2024. Parents of children older than 1 year with persistent visible IH associated with psychosocial distress were offered vascular laser therapy or topical timolol treatment. Because topical therapy could be administered safely at home under remote medical supervision during ongoing military action, all families chose this option. A short initial treatment period of 2-4 weeks was used to assess the therapeutic response, and treatment was continued if improvement was observed. A total of 2419 children with IH were evaluated during the study period. Among them, 1287 patients used topical timolol as monotherapy. Treatment was initiated after the age of 1 year in 113 patients with persistent lesions. Positive outcomes were observed in 1151 (98.04%) patients who started therapy before the age of 1 year and in 78 (69.03%) patients who initiated treatment between 1 and 5 years of age (p < 0.001). Topical timolol 0.5% demonstrated limited effectiveness in older children, whereas switching to topical timolol 1% resulted in clinical improvement. In six patients previously treated with systemic beta-blockers, topical timolol remained effective even after systemic therapy had lost effectiveness. Natural involution of IHs may be partially responsible for the positive effect observed in some of our patients. These findings suggest that topical timolol 1% may provide clinically meaningful improvement in persistent IH beyond infancy and support telemedicine-based treatment when access to in-person care is limited.Keywords
This publication has 27 references indexed in Scilit:
- Diagnosis and management of infantile hemangiomas: Tremendous advances over the last 15 yearsLa Presse Médicale, 2025
- The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort studyEuropean Journal of Pediatrics, 2025
- The 595‐nm Wavelength Pulsed Dye Laser for Pediatric Port‐Wine Birthmarks and Infantile Hemangiomas: A Systematic ReviewLasers in Surgery and Medicine, 2024
- Treatment of telangiectasias with a 595-nm pulsed dye laser following hemangioma involution: a retrospective analysisLasers in Medical Science, 2024
- Infantile HemangiomasDermatologic Clinics, 2022
- Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessmentJournal of the American Academy of Dermatology, 2021
- Infantile hemangioma. Part 2: ManagementJournal of the American Academy of Dermatology, 2021
- Adverse effects of topical timolol: Safety concerns and implications for dermatologic useJournal of the American Academy of Dermatology, 2021
- Review of topical beta blockers as treatment for infantile hemangiomasSurvey of Ophthalmology, 2016
- Hemangiomas of Infancy: Epidemiology2009